Moving the HIV vaccine field forward: concepts of protective immunity

Stephen J. Kent, Miles P. Davenport

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Vaccine-induced prevention of HIV infection is widely viewed as requiring both humoral and cellular immunity. Although the evidence for such a multipronged approach is not strong, this strategy increases the possibility that at least one mechanism of immunity could work to diminish new infections. The concept of broad immunity to HIV is attractive to funding bodies that seek at least some success from expensive trials. However, trying simultaneously to achieve both robust cellular and humoral immunity against HIV might be difficult. Furthermore, a multipronged approach increases the difficulty of later dissecting the immune correlates of protection and thereby iteratively improving HIV vaccines. This Viewpoint briefly discusses different approaches to tackling the challenge of inducing protective immunity to HIV and speculates on how results will move the field forward. We posit that, given the uncertain nature of immunity to HIV at present, focusing on inducing, evaluating, and optimising discrete individual mechanisms of immunity to HIV could provide the most rapid pathway to an effective HIV vaccine.

Original languageEnglish
Pages (from-to)e406-e410
Number of pages5
JournalThe Lancet HIV
Volume6
Issue number6
DOIs
Publication statusPublished - 1 Jun 2019

Cite this

Kent, Stephen J. ; Davenport, Miles P. / Moving the HIV vaccine field forward : concepts of protective immunity. In: The Lancet HIV. 2019 ; Vol. 6, No. 6. pp. e406-e410.
@article{8454bb484c48457fbfa9981efc8ddb10,
title = "Moving the HIV vaccine field forward: concepts of protective immunity",
abstract = "Vaccine-induced prevention of HIV infection is widely viewed as requiring both humoral and cellular immunity. Although the evidence for such a multipronged approach is not strong, this strategy increases the possibility that at least one mechanism of immunity could work to diminish new infections. The concept of broad immunity to HIV is attractive to funding bodies that seek at least some success from expensive trials. However, trying simultaneously to achieve both robust cellular and humoral immunity against HIV might be difficult. Furthermore, a multipronged approach increases the difficulty of later dissecting the immune correlates of protection and thereby iteratively improving HIV vaccines. This Viewpoint briefly discusses different approaches to tackling the challenge of inducing protective immunity to HIV and speculates on how results will move the field forward. We posit that, given the uncertain nature of immunity to HIV at present, focusing on inducing, evaluating, and optimising discrete individual mechanisms of immunity to HIV could provide the most rapid pathway to an effective HIV vaccine.",
author = "Kent, {Stephen J.} and Davenport, {Miles P.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/S2352-3018(19)30134-1",
language = "English",
volume = "6",
pages = "e406--e410",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier",
number = "6",

}

Moving the HIV vaccine field forward : concepts of protective immunity. / Kent, Stephen J.; Davenport, Miles P.

In: The Lancet HIV, Vol. 6, No. 6, 01.06.2019, p. e406-e410.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Moving the HIV vaccine field forward

T2 - concepts of protective immunity

AU - Kent, Stephen J.

AU - Davenport, Miles P.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Vaccine-induced prevention of HIV infection is widely viewed as requiring both humoral and cellular immunity. Although the evidence for such a multipronged approach is not strong, this strategy increases the possibility that at least one mechanism of immunity could work to diminish new infections. The concept of broad immunity to HIV is attractive to funding bodies that seek at least some success from expensive trials. However, trying simultaneously to achieve both robust cellular and humoral immunity against HIV might be difficult. Furthermore, a multipronged approach increases the difficulty of later dissecting the immune correlates of protection and thereby iteratively improving HIV vaccines. This Viewpoint briefly discusses different approaches to tackling the challenge of inducing protective immunity to HIV and speculates on how results will move the field forward. We posit that, given the uncertain nature of immunity to HIV at present, focusing on inducing, evaluating, and optimising discrete individual mechanisms of immunity to HIV could provide the most rapid pathway to an effective HIV vaccine.

AB - Vaccine-induced prevention of HIV infection is widely viewed as requiring both humoral and cellular immunity. Although the evidence for such a multipronged approach is not strong, this strategy increases the possibility that at least one mechanism of immunity could work to diminish new infections. The concept of broad immunity to HIV is attractive to funding bodies that seek at least some success from expensive trials. However, trying simultaneously to achieve both robust cellular and humoral immunity against HIV might be difficult. Furthermore, a multipronged approach increases the difficulty of later dissecting the immune correlates of protection and thereby iteratively improving HIV vaccines. This Viewpoint briefly discusses different approaches to tackling the challenge of inducing protective immunity to HIV and speculates on how results will move the field forward. We posit that, given the uncertain nature of immunity to HIV at present, focusing on inducing, evaluating, and optimising discrete individual mechanisms of immunity to HIV could provide the most rapid pathway to an effective HIV vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85066267235&partnerID=8YFLogxK

U2 - 10.1016/S2352-3018(19)30134-1

DO - 10.1016/S2352-3018(19)30134-1

M3 - Article

VL - 6

SP - e406-e410

JO - The Lancet HIV

JF - The Lancet HIV

SN - 2352-3018

IS - 6

ER -